TheEdgeResearch
Home / Stocks / AMAM

Ambrx Biopharma Inc. (AMAM)

NYSE Healthcare Biotechnology
$28.00 ▲ +0.07%
Market Cap
$1.77B
Sector
Healthcare
Industry
Biotechnology
Beta
-2.36
52-Wk Range
6.55-28.15
CEO
Daniel J. O'Connor
Country
US
Currency
USD

Ambrx Biopharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $28.00, up 0.07% on the session, giving a market capitalisation of $1.77B. On trailing twelve-month figures it carries a trailing P/E of -13.86, a net margin of -1053.7%. Its beta of -2.36 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-13.86
Price / Sales
239.41
Price / Book
9.17
EV / EBITDA
-27.36
Gross margin
100.0%
Operating margin
-771.2%
Net margin
-1053.7%
Return on equity
Debt / equity
0.10
Current ratio
5.44
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
87
IPO date
2023-08-14
Headquarters
La Jolla, CA, US
About Ambrx Biopharma Inc.

Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.

Comparable companies

Ambrx Biopharma Inc. is most often compared with the following Healthcare names:

BIESFBLUDICEEQRXFUSNKDMNNAGEPNTSRRAZGNX
More research on AMAM
AMAM technical analysis AMAM TheEdge Score Compare against peers
Open full interactive analysis & DCF →